A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
BACKGROUND: This study examines gastrointestinal adverse events (GIAEs) associated with tirzepatide using bibliometric and pharmacovigilance analyses. RESEARCH DESIGN AND METHODS: A bibliometric analysis of Web of Science data identified research tre…
Tirzepatide is well known for its glucose-lowering and weight-reducing effects, primarily through central appetite suppression. However, its direct role in promoting white adipose tissue (WAT) browning and the underlying mechanisms remain unclear. We…
INTRODUCTION: Water fasting involves completely abstaining from all caloric intake. Multiple studies have demonstrated that water fasting for up to 21 days is well-tolerated, but none focused on patients with severe obesity (body mass index ≥ 40) or…
Incretin-based therapies currently represent one of the cornerstones in the management of type 2 diabetes mellitus and obesity, owing to their ability to integratively modulate cardiometabolic risk. Semaglutide, a selective agonist of the glucagon-li…
Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their ability to reduce major adverse cardiovascular events (MACEs) among at-risk patients living with type 2 diabetes (T2D). Tirzepatide, a dual GIP/GLP-1 receptor agonist, dem…
[This corrects the article DOI: 10.1371/journal.pone.0285197.].
BACKGROUND: Tirzepatide is a dual-acting glucagon-like peptide-1 analog and a glucose-dependent insulinotropic polypeptide analog. The disease-specific weight-reducing effects associated with tirzepatide use are well established, but its adverse effe…
Developed to treat type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been associated with a reduced risk of cardiovascular events in high-risk patients with diabetes, and later in obese patients with cardiovascular disease w…
PURPOSE OF REVIEW: Overweight and obesity are increasingly common in people with type 1 diabetes mellitus (T1DM). This narrative review synthesizes current evidence on the epidemiology and mechanisms linking excess adiposity with T1DM, the obesity-as…
Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists and tirzepatide, a dual GLP1R and glucose-dependent insulinotropic polypeptide receptor agonist, have become fundamental in managing type 2 diabetes mellitus (T2DM) and obesity due to their pot…
New obesity medications have demonstrated efficacy in trials, but their real-world deployment is partly limited by the absence of approaches that identify individuals for treatment based on risks for obesity-related complications. Here we present a r…
AIMS: Targeting the glucose dependent insulinotropic polypeptide receptor (GIPR) is of growing interest for treating type 2 diabetes and obesity, though the optimal approach remains unclear. Both GIPR agonism and antagonism, respectively, incorporate…
BACKGROUND: Cardiovascular disease (CVD) and chronic kidney disease (CKD) frequently coexist, with obesity and type 2 diabetes (T2D) being major contributors to adverse outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide ha…
Heart failure with preserved ejection fraction (HFpEF) affects 32 million people worldwide and is responsible for tens of billions of dollars in healthcare expenditure annually, with costs primarily driven by hospitalizations. HFpEF is notoriously di…
BACKGROUND: Incretin-based therapies induce substantial weight loss and are widely prescribed; disproportionate losses in fat-free mass (FFM) and skeletal muscle are a concern. PURPOSE: To evaluate body composition changes associated with incretin th…